
BIOA LEGAL DEADLINE: BioAge Labs Investors that Lost Money are Reminded of Pending Class Action – Contact BFA Law by March 10 Court Deadline (NASDAQ:BIOA)
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws.
If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Investors have until March 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering held on or about September 26, 2024. The case is pending in the U.S. District Court for the Northern District of California and is captioned Soto v. BioAge Labs, Inc., et al., No. 25-cv-196.
Why was BioAge Sued under the Federal Securities Laws?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company's lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.
As alleged, BioAge's IPO documents discussed its ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists for enhanced weight loss. BioAge stated that it was collaborating with Eli Lilly and Company ('Lilly') in connection with STRIDES, and that Lilly would be advising and assisting on all aspects of the trial's design and execution. BioAge also stated that it anticipated topline results in Q3 2025 and discussed the potential for a second Phase 2 clinical trial. As alleged, BioAge's statements conveyed to investors that there were no safety concerns and that it expected top line results to meet its primary endpoint goals.
In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company terminated the trial and ceased further enrollment.
The Stock Declines as the Truth is Revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The Company stated that the decision to discontinue the STRIDES trial of azelaprag 'became clear' due to 'the emerging safety profile of the current doses tested[.]' This news caused the price of BioAge stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: .
What Can You Do?
If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Or contact:
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
18 minutes ago
- CNBC
Stock futures are little changed after S&P 500 ends three-day win streak: Live updates
Traders wait for Voyager Technologies to begin trading during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., June 11, 2025. Brendan McDermid | Reuters Stock futures were relatively unchanged on Wednesday after the S&P 500 saw its first negative session in four. S&P 500 futures traded down by 0.1%, along with Nasdaq 100 futures . Futures tied to the Dow Jones Industrial Average dropped 44 points, or 0.1%. In extended trading, shares of Oracle surged more than 7% after its fiscal fourth-quarter results beat on the top and bottom lines. The company also indicated more cloud growth ahead, saying in a statement that cloud infrastructure revenue will rise by more than 70% in fiscal 2026, up from a 50% growth rate in the prior fiscal year. Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq Composite . But the moves were slight. The broad market index fell about 0.3%, while tech-heavy Nasdaq dropped 0.5%. The Dow Jones Industrial Average was flat. While the day's losses put the S&P 500 a bit further away from reaching a new record high, the index is also still just more than 2% below its late February record. Those moves come after consumer prices rose less than expected in May, as the consumer price index increased 0.1% for the month. That's less than the Dow Jones forecast for 0.2%. Core CPI, which excludes food and energy prices, also increased less than expected. "I don't think the market has a lot of faith that we're not going to see at least a little bit higher inflation," Scott Wren, senior global market strategist at Wells Fargo, told CNBC's "Closing Bell" Wednesday. "With all the things going on, the economy slowing, earnings growth likely to slow, lots of trade negotiations to still work through, is there really a good reason to take a run at the record high? I don't know about that. It makes a lot of sense to me that we'd be choppy and maybe see a little downside here." Investors are now looking ahead to May's reading of the producer price index, due out at 8:30 a.m. ET on Thursday. Economists polled by Dow Jones are expecting the index to show a gain of 0.2% for the period. Subtracting out food and energy, core PPI is expected to show growth of 0.3% on the month. The Street is also waiting for more developments on trade, especially between the U.S. and China, as talks between the two countries have been a focal point this week. While officials reached an agreement in London, the deal still awaits approval from U.S. President Donald Trump and Chinese President Xi Jinping. Trump said in a post on Truth Social earlier Wednesday that "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%." However, Commerce Secretary Howard Lutnick later said that U.S. levies on goods from China won't change from their current levels. Rising tensions between the U.S. and Iran will also be in focus. U.S. crude oil futures jumped more than 4% on Wednesday after Trump expressed doubt that the two countries could reach a nuclear deal.


Business Wire
28 minutes ago
- Business Wire
Walker & Dunlop's Built-For-Rent Report Highlights Accelerated Growth
BETHESDA, Md.--(BUSINESS WIRE)-- Walker & Dunlop, Inc. released its 2025 Built-For-Rent (BFR) report, that offers comprehensive market trends and analysis on the rapid expansion of this housing sector. As a leader in this space, Walker & Dunlop has facilitated over $3.4 billion in BFR financing and investment sales, providing expert guidance to developers and investors navigating this dynamic asset class. 'BFR has emerged as a fast-growing and highly strategic segment within multifamily real estate,' said Walker Harris, senior vice president and co-head of Multifamily at Walker & Dunlop. 'Fueled by evolving renter preferences, constrained for-sale inventory, and widening affordability challenges in homeownership, BFR presents renters with a unique option: purpose-built single-family homes combined with the flexibility of renting.' The report explores the current BFR market, the advantages and challenges of BFR investment, and the ways in which Walker & Dunlop facilitates strategic investment in the BFR space. Why BFR Demand Is Accelerating: A Shifting Renter Profile: Renters choose BFR for lifestyle and flexibility, enjoying home-like features without mortgage commitments. Supply-Demand Imbalance: Rental housing demand exceeds supply as population growth outpaces new single-family home construction. Affordability Gap Widens: Rising homeownership costs make buying less affordable, increasing interest in BFR communities. Rent vs. Own: A Compelling Cost Comparison: BFR renting often costs significantly less than owning a comparable home, offering notable savings. For owners and investors, BFR offers institutional-grade stability by combining single-family home appeal with multifamily management, leading to stable cash flow and higher occupancy rates around 96%. Its diverse product types—detached homes, townhomes, and horizontal apartments—allow tailored investment strategies, with single-family detached homes often commanding the highest prices for closely mimicking traditional homeownership. 'At Walker & Dunlop, we provide comprehensive capital solutions tailored to every stage of the Built-For-Rent lifecycle, from development and acquisition to investment,' said Keaton Merrell, managing director of Capital Markets at Walker & Dunlop. 'As the #1 Fannie Mae DUS® lender in 2024, we offer clients access to scalable, attractive financing alongside a broad range of debt and equity options. Our deep market expertise and expansive network enable us to deliver customized advisory services that help clients mitigate risk and accelerate execution. We are proud to be a trusted partner driving growth and stability in this dynamic sector.' For insights on BFR and to explore key trends shaping the market, download Walker & Dunlop's 2025 Built-For-Rent report here. About Walker & Dunlop Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.
Yahoo
36 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data